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Chapter 1: Review: 
Roles of Extracellular Vesicles (EVs) in HIV-1 Pathogenesis and Implications for 
HIV-1 Eradication 
 
1.1 HIV-1 Infection and Latency 
Acquired Immunodeficiency Syndrome (AIDS) still is one of the most 
daunting epidemics in human history. Following the initial diagnosis of the first 
AIDS patient in the United States1, significant progress been made towards 
understanding the disease, and enormous efforts from both the scientific and 
medical communities have ended the status of AIDS as a death sentence.  
Human Immunodeficiency Virus (HIV-1 or HIV) was identified as the 
infectious, causative agent of AIDS in 1983. Since then, efforts of the scientific 
and medical communities to identify and administer effective antiviral treatments 
have transformed HIV/AIDS from a “death sentence” to a manageable chronic 
condition. Nevertheless, to date, HIV-1 has claimed more than 35 million lives2, 
and it continues to threaten global health with 1.8 million new infections 
diagnosed in 20172.  HIV has also created a substantial economic burden. In the 
United States alone, the aggregate cost of people living with HIV/AIDS was 
approximately $10.7 billion higher than the costs of those living without 
HIV/AIDS from 2002 to 20113.  
HIV-1 belongs to the Lentivirus genus of the Retroviridae family and has 
two groups of isolates: HIV-1 and HIV-24. Like other viruses in the Lentivirus 
family, HIV-1 has a chronic disease progression, with a long period of latency, 
persistent viral replication, and central nervous system (CNS) involvement4. The 
HIV-1 virion has a diameter of around 100 nm and is enclosed by a lipid bilayer 
membrane. Associated with the membrane are viral glycoproteins gp120 and gp41 
and host membrane proteins, such as ICAM-14. The HIV-1 genome consists of 
two single-stranded, positive-sense RNA molecules that contain nine genes which 
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encode for fifteen different gene products4,5. All of the structural proteins are 
encoded in the gag and env genes, while non-structural proteins such as pol, tat, 
and rev encode key effectors and modulators of HIV-1 replication4. 
HIV-1 has a multi-stage life cycle6. Virus attachment to the cell is initiated 
by the high-affinity binding of HIV-1 glycoprotein gp120 with cellular receptor 
CD4 and coreceptors CCR5 or CXCR45. Following fusion of the viral envelope 
with the cell plasma membrane, the viral core enters the cytoplasm and the RNA 
genome is reverse transcribed into a double-stranded DNA by viral reverse 
transcriptase6. The DNA provirus is then transported into the cell nucleus and 
integrated into the host genome by viral integrase6. Once integrated and 
activated, the provirus gives rise to spliced and unspliced viral RNAs, which may 
be translated into proteins or retained as full-length genomic RNA for packaging 
into virions. Progeny virions then bud from cellular membranes. Virions mature 
during and after release through the action of viral proteases, producing 
infectious particles6.  
Specific stages of the virus life cycle are targeted by pharmacologic agents 
that are collectively known as Highly Active Antiretroviral Therapy (HAART) or 
simply antiretroviral therapy (ART). The first HIV-1 treatment was 
monotherapy with azidothymidine (AZT), a reverse transcriptase inhibitor that 
initially blocked viral replication and decreased mortality and AIDS-associated 
opportunistic infections7. However, drug resistance soon evolved because of the 
error-prone nature of the viral reverse transcriptase. This outcome necessitated 
development of combination antiretroviral therapies8,9, which consist of a two- to 
four-drug regimen that stops viral replication while denying opportunities for 
evolution of resistance. Without active viral replication, the immune system 
experiences at least partial recovery of function10,11.  
Despite long-term control, HIV-1 remains incurable due to the presence of 
viral reservoirs that harbor quiescent yet replication-competent HIV-1 provirus. 
HIV-1 latency is enabled by multiple factors, including proviral integration into 
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the genome of resting CD4+ T lymphocytes, little or no viral gene expression, 
and viral sanctuary sites12. The best studied latent reservoir is memory CD4+ T-
cells13,14, but other cells including macrophages and microglia may also contribute 
to the viral reservoir15,16. Cellular reservoirse may also exisit in several anatomical 
reservoirs or sanctuaries, such as lymphoid tissues, the genital tract, the central 
CNS, and the lung17–20. Several molecular mechanisms have been uncovered to 
explain post-integration latency of HIV-1, including deleterious viral genetic 
mutation21,22, transcriptional interference23,24, chromatin epigenetic restrictions25,26, 
and absence or presence of certain cellular factors27,28. The HIV-1 latent reservoir 
is extremely stable, with a mean half-life of around 44 months, such that 
eradication is unlikely to be achieved with ART alone29.  
Diverse alternative HIV-1 eradication strategies are under active 
investigation and are a major priority in the field. These eradication approaches 
include early or intensified antiretroviral regimens30, transplantation of 
hematopoietic stem cell with anti-HIV moieties31,32, anti-HIV-1 gene 
modifications33–38, editing or excision of integrated HIV-1 provirus39–41, and “shock-
and-kill” strategies in which pharmacologic treatment reverses latency to allow 
for the elimination of infected cells by host immune responses or viral cytopathic 
effects42,43. Identifying a novel and combinatorial means to reverse HIV-1 latency 
remains as a priority. Recent results also suggest that extracellular vesicles (EVs) 
might be harnessed to reverse HIV-1 latency44–46.  
 
1.2 Extracellular Vesicles 
All cells, from microbes to plants and animals47–49, secrete membranous vesicles 
termed extracellular vesicles (EVs). EVs comprise a wide array of double-leaflet 
membrane extracellular particles, including exosomes and microvesicles50, and 
range in diameter from 30 nm to well over one micron (large oncosomes)51. EV 
macromolecular composition tends to reflect, but is not necessarily identical to, 
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that of the cell of origin 52. EVs have been isolated from most cells, as well as 
biological fluids 53,54. 
The first report of EVs described these entities, derived from blood plasma via 
ultracentrifugation, have procoagulant properties by Chargaff and West55, and the 
nature of these platelet-derived and lipid-containing particles was later examined 
by the Wolf56. However, more studies have highlighted the significance of EVs due 
to its capacity to transfer information to other cells in paracrine and endocrine 
fashion, thus modulating recipient cell functions54. In 1996, Raposo and colleagues 
reported these vesicles were antigen-presenting and were capable of inducing T cell 
responses57. A decade later, multiple publications sparked substantial interest in 
EVs by demonstrating that EVs contain RNA molecules, including mRNA58 and 
microRNA (miRNA)59. The vital significance of EVs was then demonstrated by 
their capacity to serve as messengers for intercellular communication in 
multicellular organisms.  
1.3 Shared Biogenesis Pathways between EV and HIV-1 
Both enclosed by a membrane and carry macromolecules such as nucleic 
acids, proteins, and such, HIV-1 virions could be considered as a special type of 
EV, in particular when we delve into the biogenesis pathway of EVs and HIV-1. 
Different types of EVs tend to have different origins, and their biogenesis 
pathways should be considered separately. Exosomes are of endosomal origin; 
their initial formation begins with the inward budding of the endosomal limiting 
membrane to form intraluminal vesicles, thus defining multivesicular bodies 
(MVBs)60,61. This process of MVB formation involves two distinct pathways: the 
endosomal sorting complex required for transport (ESCRT)45,62 and lipid domain-
induced budding60,63. Upon MVB fusion with the plasma membrane,  intraluminal 
vesicles are released as exosomes, possibly mediated by soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs)64. Considerably distinct 
from exosome biogenesis, microvesicles bud off from the plasma membrane 
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through protrusion and fission; the molecular machinery involved is still yet to be 
elucidated60,65. 
 EV biogenesis machineries are used by both nonenveloped and enveloped 
viruses66. HIV-1 can rely on host cellular machinery for its own assembly into 
nascent virions67. HIV-1 virion assembly and scission rely on viral Gag protein, 
and the detachment mediated by Gag is dependent on host proteins TSG101 and 
ALIX. Both proteins are required for cellular budding into the endosomal 
compartment by recruiting the ESCRT complex67–69. Therefore, this ESCRT-
mediated biogenesis pathway is common between EV and HIV-1 biogenesis. HIV-
1 developed this strategy to divert this machinery to sites of virion assembly to 
aid for its release in a topologically conserved fashion67.  
 
1.4 Pro-viral Effects of EVs on HIV-1 
Upon HIV-1 infection, EVs shed from infected cells may facilitate disease 
progression as “accomplices,” through the transfer of host or viral components to 
uninfected cells while also evading host immune surveillance 70. For example, Nef 
protein, an viral accessory protein that is expressed in the early stages of the 
viral life cycle71, can stimulate its own exit by the release of EVs, and released 
Nef proteins can cause activation-induced cell death of resting peripheral blood 
lymphocytes72. The transfer of virus-encoded Nef protein can contribute to 
suppression of humoral immunity through impairing IgG2 and IgA antibody class 
switching73. Nef proteins are also capable of counteracting SERINC3/5, host 
restriction factors against retroviral infection, by restoring virion infectivity74. Nef 
proteins can also impair T cell activation by interfering with trafficking Luk and 
LAT to the immunological synapse75. EVs released from HIV-1 infected cells can 
also carry viral Env (gp120) protein76, and the delivery of this protein to 
uninfected cells may facilitate HIV-1 infection indirectly through the inhibition of 
plasmacytoid dendritic cells (pDCs)77 and the interaction with cellular integrin 
𝛼"𝛽$78. 
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 EVs from infected cells and in patient blood can contain HIV-1 ncRNAs, 
such as trans-activating response (TAR) element RNA, which could make a naive 
target cell more susceptible to HIV-1 infection79. These TAR RNAs can also 
stimulate the production of pro-inflammatory cytokines IL-6 and TNF𝛽, which 
could exacerbate inflammatory responses in chronic HIV-1 infection80. Other 
reported virus-derived microRNAs (miRNAs), called vmiR88 and vmiR99, may 
also be present in EVs isolated from infected cell culture and HIV-1 positive 
patient blood81. These vmiRs could potentially lead to chronic immune activation, 
thus enhancing HIV-1 infection indirectly81. Intact HIV-1 virions could be 
transmitted in EVs from infected dendritic cells to CD4+ T cells without de novo 
infection82. 
Also, by differentially incorporating and excluding certain host 
immunoregulatory molecules such as CD86 and CD80, EVs derived from certain 
infected cell lines could compromise CD4+ T lymphocytes functions83. EVs 
derived from infected cells could transfer HIV-1 coreceptors CCR5 and CXCR4 
to other cells that are typically resistant to HIV-1 infection, and ultimately confer 
or enhance HIV-1 infection in these cell types84,85.  
 
1.5 Antiviral Effects of EVs on HIV-1 
EVs released from uninfected cells are also capable of inhibiting viral 
propagation via multiple routes. One study has illustrated that EVs secreted 
from CD8+ T cells display potent noncytotoxic antiretroviral activity by 
inhibiting integrated HIV-1 transcription86. EVs purified from biofluids of HIV-1 
seronegative donors have also demonstrated potency in inhibiting cell-to-cell 
trans-infection. EVs isolated from breast milk have been shown to block dendritic 
cell (DC)-mediated viral transfer to CD+ T cells by binding to DC-SIGN87. 
Healthy donor semen also contains EVs that can block HIV-1 post-entry 
replication by inhibiting reverse transcriptase (RT) activity88. Semen-derived EVs 
also have anti-inflammatory properties, and these properties could be beneficial 
+!
to the host by reducing the extent of HIV-1-induced inflammation and cell 
activation89,90.   
Similarly, EVs can exert their modulatory effects by transferring multiple 
types of antiviral effector molecules to the recipient cells, thus blocking viral 
infection or restricting viral propagation. Various publications have verified the 
enrichment of a myriad of mRNAs that are classified as host restriction factors, 
such as APOBEC3 family members and BST-2/tetherin88,91,92. Anti-HIV-1 
microRNAs (miRNAs), such as miR-28 and miR-223, have also been reported to 
be enriched in EVs93,94.   
!
Figure 1 Proviral and Antiviral Effects of EV on HIV Infection. 
EVs released from HIV infected cells can contain both viral and host factors to facilitate 
viral infection by priming uninfected cells. EVs derived from healthy cells and various 
biofluids have the potential of suppressing HIV infection by inhibiting HIV replication 
through the transfer of restriction factors.  
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1.6 Effect of EVs on HIV-1 Latency/Reactivation 
EVs not only have broad implications in mediating acute HIV-1 infection, 
but various studies have also indicated that EVs could potentially serve as the 
effector of activating latently infected viral reservoirs to maintain a transient 
viremia during the course of the disease. Arenaccio and colleagues discovered that 
latent HIV-1 could be reactivated upon exposure to EVs released by infected 
cells46. This finding was validated in both cell lines and primary cell cultures. 
They also provided evidence that ADAM17 molecules loaded into these EVs 
could trigger the reactivation via the Nef-ADAM17-TNFα axis46,95. Interestingly, 
this finding was corroborated in a non-human primate animal model—rhesus 
macaques96.  
However, two years after the aforementioned paper was published, the 
Kashanchi lab found that EVs derived from uninfected cells can also reactivate 
HIV-1 basal transcription in latently infected cells by phosphorylation of RNA 
polymerase II on the HIV-1 promoter45. EVs isolated from healthy cells of various 
lineages were exposed to different cell lines chronically infected with wild-type 
viruses, such as ACH2 (lymphocytic cell line), U1 (monocytic line), and OM10.1 
(premyeloid line) cells45. By mixing and matching donor EVs and recipient cell 
lines, Barclay et al. discovered that autologously sourced EVs are superior at 
activating HIV-1 latency, possibly due to lineage specificity between the cell 
types that the EVs were derived from and the recipient cell types45.  
Recent evidence from our lab has demonstrated an alternative possibility of 
reversing HIV-1 latency by withdrawing EVs from latently infected U1 and 
ACH2 cell lines44. Under EV-depleted conditions, these two cell lines each 
underwent viral reactivation to a certain degree, and further functional analyses 
indicated that alterations in cellular lipid production could be a potential 
underlying mechanism for this reactivation44. In the same study, we demonstrated 
that HIV-1 virions produced in the EV-depleted condition were more infectious, 
and cells cultured in this depleted condition were more susceptible to infection44. 
-!
From these results, we concluded that EVs and other serum particles, which are 
commonly replete both in vitro and in vivo, could inhibit HIV-1 infection and 
production44. Together, these studies suggest that manipulating EVs in the 
cellular environment, or modulating cellular recognition of EVs, could be used to 
affect HIV latency.  
Whether it is supplying EVs isolated from infected or uninfected cells or 
depleting serum EVs from the culture medium, and despite some contrasting 
conclusions, these data collectively emphasize that EVs have roles in HIV-1 
latency. The necessity of fundamentally understanding the molecular interplay 
between EV homeostasis and HIV-1 latency maintenance in HIV-1 reservoirs calls 
for the identification of host factors that are associated with recognition of 
extracellular particles that contribute to the maintenance of HIV-1 latency.   
Figure 2 Effects of EVs on HIV Latency 
Different routes that EVs can reactivate HIV latently infected cells: 1. Exposure of EVs 
derived from HIV-infected cells to HIV latent cells can activate HIV replication through 
the Nef-ADAM17-TNF� axis; 2. Exposure of EVs derived from uninfected cells to HIV 
latent cells; 3. Withdrawal of EVs derived from uninfected cells to HIV latent cells."  
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Chapter 2: Engineering an iCRISPR HIV Reporter 
Cell Line to Investigate Mechanisms of Extracellular 
Vesicle Sensing and HIV Latency 
 
2.1 Introduction:  
 
A cure for HIV-1 is a priority in today’s scientific community despite 
effective combination antiretroviral therapy. Identifying novel approaches for 
latent reservoir eradication are currently in progress, and preliminary results from 
our lab and others suggest the possibility of harnessing extracellular vesicles 
(EVs) in novel HIV-1 eradication approaches44. EVs and HIV are closely related, 
and HIV virions can be even regarded as a specialized type of EVs subverted by 
the retroviral genomic reprogramming.  
As EVs are commonly replete in cell culture medium due to the usage of 
bovine and human sera, it is crucial to minimize exogenous EVs from culture 
medium so as analyze endogenous EVs produced by the cells of interest. We have 
previously reported that depleting EVs from the culture medium of HIV infected 
cells affects various aspects of the retroviral life cycle44. Most importantly, EV 
depletion from culture media leads to increased HIV production by acutely 
infected cells and relaxes latency in both T-cell and monocyte-linage latency 
models in vitro44. By using gene arrays and lipidomics, we assessed cellular 
changes in response to EV depletion, and demonstrated that both the host RNA 
transcripts and the lipid products of specific lipid synthesis pathways (e.g., sterol 
biosynthesis) were significantly upregulated by cells exposed to EV-depleted 
conditions44. Hence, in the relative absence of serum lipid-containing particles 
such as EVs, lipids involved in both EV and virion biogenesis are upregulated 
(Figure 1A, B). 
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Therefore, we hypothesized that enhanced lipid synthesis was a 
compensatory response to the perceived loss of the exogenous source of lipids 
transferred by EVs. In turn, HIV virions are more likely to bud through 
membrane microdomains such as lipid rafts; hence this may explain our 
observation of HIV upregulation. There must exist host mechanisms for 
monitoring incoming EVs or associated particles that likely involve cell 
membrane proteins or membrane trafficking components (Figure 1C). By 
manipulating these host mechanisms, perhaps we can mimic the effects of EV 
depletion, to reserve HIV latency and ultimately eradicate HIV.  
 
 
Figure 3. Visual illustration of project rationale.  
A) When extracellular vesicles and other serum particles were present in cell 
culture medium, HIV latent cell lines remained latent, with minimal HIV-1 
replication. B) When these particles were depleted from the cell culture, HIV 
latent cell lines became reactivated with a noticeable increase in HIV-1 
production. C) We propose to mimic EV-depleted condition by knocking out EV 
sensing and trafficking machinery (blue crosses), and identify pathways which 
may potentially contribute to the maintenance of HIV latency. 
 
 12 
Here, through CRISPR-mediated focused genetic screening, we propose to 
identify and target host factors associated with recognition of extracellular 
particles that could contribute to HIV-1 latency maintenance. A recent 
publication by González and colleagues has demonstrated an efficient and 
versatile CRISPR/Cas9 mediated genome editing system in hESCs97,98. As 
compared with the transient expression of genes that are mediated by plasmid 
delivery, stably integrated and inducible Cas9 expression exhibits numerous 
benefits as it allows a versatile yet precise expression of the invariable Cas9 
protein in the CRISPR system. The variable gRNA component can be easily 
supplied by transfection due to its small size, allowing for rapid and efficient 
genetic screening. For better control of gene expression, González and colleagues 
used TALEN-mediated gene targeting into the AAVS1 locus97,98, which has been 
a validated safe harbor for sustained transgene expression in human cells99. 
However, instead of TALEN-mediated gene targeting, we chose CRISPR-
mediated gene targeting due to its high efficiency and technical convenience100.  
We established the iCRISPR platform through CRISPR-mediated 
targeting of inducible Cas9 expression cassettes into TZM-bl cell line for the 
initial screening of membrane trafficking and cell surface proteins. Successful 
transgenic insertion of Cas9 protein while maintaining the integrity of the 
parental cell line was comprehensively validated on DNA, protein, and functional 
levels. We have established a reliable engineering method for the inducible and 
stable expression of Cas9 in vitro, thus providing a versatile tool for HIV-related 
genetic screening. 
 
2.2 Materials and Methods: 
Cell culture:  
TZM-bl cells(Cat. # 8129) and J-Lat full length cells (8.4) (Cat. # 9847) were 
obtained from the NIH AIDS Research and Reference Reagent Program. TZM-bl 
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was cultured in complete DMEM medium (D10) prepared with 10% heat-
inactivated FBS (GE Healthcare Life Sciences, USA. Cat #: SH3039603), 1mM 
L-glutamine (Thermo Fisher, MA, USA; Cat #25030081), 1mg/mL Pen-Strep 
(Thermo Fisher, MA, USA; Cat #15140148), and 10mM HEPES (Thermo 
Fisher, MA, USA; Cat #15630080). J-Lat clones 8.4 was cutured in complete 
RPMI (R10) prepared with the same supplemental reagents as D10. Both cell 
lines were cultured in vented T-75 culture flasks (Corning Costar, PA, USA. Cat 
#: 430641U). Cells were incubated at 37flC in humidified 5% 𝐶𝑂( environment. 
TZM-bl cell monolayer was split 1:10 at confluency by treatment with 1X 0.25% 
trypsin, 1 mM Ethylenediaminetetraacetic acid (EDTA) (Gibco, Canada. Cat #: 
15400-054, Lot #: 2027369) as described65. J-Lat 8.4 cells were split 1:3 around a 
concentration of 1 × 10,cells/mL. 
 
Plasmids:  
All three plasmids were obtained from Addgene. AAVS1 T2 CRIPR in pX330 
plasmid was deposited by the Kanemaki lab (Addgene plasmid #72833). Puro-
Cas9 donor plasmid was deposited by the Huangfu Lab (Addgene plasmid 
#58409). Neo-M2rtTA donor plasmid was deposited by the Jaenisch Lab 
(Addgene plasmid #60843). 
 
Plasmid Isolation and Characterization:  
Plasmid propagation: 
Plasmids were obtained as bacterial stabs from Addgene. They were then 
individually plated on LB agar plates containing 100 μg/mL ampicillin (Quality 
Biological, MD, USA. Cat#: 340-108231; Lot#: 722888). E. coli containing Puro-
Cas9 and M2rtTA donor plasmids were cultured overnight at 30flC (37flC for E. 
coli containing AAVS1 T2 CRIPR plasmid). After visible single colonies formed, 
liquid cultures were made by inoculating 2mL of LB (Quality Biological, MD, 
%(!
USA. Cat#: 340-004101; Lot#: 722699) + 100 0g/mL ampicillin sodium salt 
(Sigma-Aldrich, MO, USA. Cat #: A9518-5G, Lot #: BCBG2945V) with a single 
colony from the respective LB agar plates. Liquid cultures were incubated at 
their appropriate temperatures (30flC for E. coli containing Puro-Cas9 and 
M2rtTA donor plasmids and 37flC for E. coli containing AAVS1 T2 CRIPR 
plasmid) overnight with rigorous shaking (300rpm). To obtain large volume for 
plasmid DNA maxiprep, 1mL of overnight liquid culture was added into 300 mL 
LB+1000g/mL ampicillin. Flasks were incubated with shaking at appropriate 
temperatures (30flC for E. coli containing Puro-Cas9 and M2rtTA donor 
plasmids and 37flC for E. coli containing AAVS1 T2 CRIPR plasmid) overnight.
Plasmid Maxiprep: 
Transfection grade plasmid DNA were isolated using the EndoFree� Plasmid 
Purification Kit (Qiagen, Hilden, Germany. Cat #: 12362. Lot#: 160029720) as 
per the manufacturer!s protocol. Isolated DNA was eluted in 250 0L nuclease-free 
water (Qiagen, Hilden, Germany. Cat #: 1039480, Lot #: 160034794). DNA 
concentration was then determined using NanoDrop  One/OneC Microvolume 
UV Spectrophotometer (ThermoFisher, DE, USA. Machine #:0094684).  
Restriction Enzyme Digest: 
One 0g of each plasmid was combined with 50L of 10X CutSmart Buffer (New 
England Biolabs, MA, USA. Cat #: B7204S, Lot #: 2861712) and 1 0L of each 
endonuclease (New England Biolabs, MA, USA) as indicated in Table 1. The 
final reaction mixture was completed with RNase-free water to a final volume of 
50 0L. 
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Plasmid Endonucleases Used 
Puro-Cas9 Donor 
AgeI HF(Cat #: R3552S. Lot #: 0041411), SpeI 
HF (Cat #: R3133S. Lot #: 0131702) 
Neo-M2rtTA Donor 
EcoRV HF (Cat #: R3195S. Lot #: 0051206), 
NheI HF (Cat #: R3131S. Lot #: 0021311) 
AAVS1 T2 CRIPR in 
pX330 
EcoRI HF (Cat #: R3101S. Lot #: 0131604), 
XbaI (Cat #: R0145S. Lot #: 0431708) 
Table 1. Restriction Enzymes Used for Digestion Reaction of All Three Plasmids.  
 
Reaction mixture was incubated for 1 hour at 37˚C on a Thermomixer 
(Eppendorf, Hamburg, Germany. Machine #: 53552K747628), after which the 
endonucleases were inactivated at 65 ˚C for 20 mins (SpeI was inactivated at 80 
˚C for 20 mins). 
Gel Electrophoresis: 
1% agarose was made by dissolving 1g of Ultrapure agarose (Invitrogen, 
CA, USA. Cat #: 16500-500, Lot #: 0000481896) in 100mL of 1X TAE buffer 
(40 mM Tris-acetate, 1 mM EDTA) (Invitrogen, Vilnius, Lithuania. Cat #: 
AM9869, Lot #: 00534786); then the mixture was microwaved until clear. The 
molten agarose solution was then poured into the casting apparatus with a comb 
until it was cooled. The gel was then allowed to cool to room temperature and 
then placed into the gel box. 6μL of 6X DNA loading dye (ThermoFisher, MA, 
USA. Cat #: R0611, Lot #: 00606810) was added to each 10 μL of each DNA 
sample to be separated, along with 8μL of 1kb DNA ladder (ThermoFisher, 
Vilnius, Lithuania. Cat #: SM0313, Lot #: 00182322). Sufficient amount of 1X 
TAE was then poured into the gel box to fully immerse the gel. The comb was 
lifted and all DNA samples were loaded into the appropriate wells according to 
the plate map. Power supply was then connected to the gel box and the gel was 
run at 80V for 10 mins and then the power was increased to 100V for one hour. 
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After the gel was run, it was retrieved from the gel box and then stained in 
running buffer containing 0.5 μg/mL ethidium bromide (Amresco, Ohio, USA. 
Cat #: E406-5ML, Lot #: 3197C436) for 15 mins. The gel was then visualized in 
a GelDoc Imager (Biorad, CA, USA. Machine #: 0086277) using the appropriate 
tray. The gel was auto-exposed for 10 secs, optimized for intense bands. 
Sanger Sequencing of iCRISPR Plasmids: 
DNA samples were prepared according to Genewiz’s protocol (Genewiz, 
Inc, NJ, USA). For each sequencing reaction, plasmid templates were diluted to 
around 100ng/μL and 10 μL was aliquoted into 8-strip PCR tubes (BioRad, CA, 
USA. Cat #:TLS0801, Lot #: BR00433874). Primers used for sequencing all 3 
plasmids and their sequences are shown in Table 2: 
 
Plasmid Primer Sequence (5’-3’) 

























Table 2. Sequences of Sanger Sequencing Primers for All Three Plasmids. 
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A total amount of 25 pmol was used for each sequencing reaction and they were 
mixed with template at the facility. The sequencing reaction volume was 15 μL.  
 
TZM-bl Transfection and Selection: 
Lipofectamine 2000 Transfection: 
TZMbI cells were seeded at 4× 10,cells per well into 12-well plates the day before 
transfection. TZMbI cells were transfected with 2 μg of plasmids in total in 
varying combinations using Lipofectamine 2000 (Invitrogen/Life Technologies, 
Carlsbad, CA Cat #: 11668-019 Lot #:1467572) diluted in OptiMEM Reduced 
Serum Medium (Gibco, Grand Island, NY Cat #: 31985-070 Lot #: 1762285). 
Controls included mock transfections and transfection of 2 μg of pmaxGFP 
plasmids obtained in Cell Line NucleofectorTM Kit C (Lonza, NJ, USA. Cat #: 
VCA-1004, Lot #: F-11982). Plates were incubated for 6 hours at 37°C. After 
incubation, successful transfection was confirmed by examining uptake of 
pmaxGFP plasmid with an Eclipse TE200 inverted microscope (Nikon 
Instruments, NY, USA. Machine #: 0072745). Transfection medium was 
removed. The plates were washed with PBS and refed with 2 mL fresh D10 
medium. 
Antibiotic Selection: 
Transfected TZMbI cells were allowed to recover for 72 hours and they 
underwent antibiotic selection per each plasmid type. For cells transfected with 
both Puro-Cas9 donor plasmid and AAVS1 T2 CRIPR plasmid, selection was 
with 0.1 μg/mL of puromycin (Gibco, China. Cat #: A11138-03/ Lot #: 
2022504) until visible single colonies were formed. For cells transfected with both 
Neo-M2rtTA donor plasmid and AAVS1 T2 CRIPR plasmid, selection was with 
300 μg/mL of G418 (Corning, VA, USA. Cat #: 30-234-CR, Lot #: 30234406) 
until visible single colonies were formed. For cells transfected with all 3 plasmids, 
%,!
selection was with 300 0g/mL of G418 and 0.1 0g/mL of puromycin. Freshly-
made selection media was changed daily. As cells approached confluency, 
antibiotic concentrations were gradually increased to 400 0g/mL of G418 and 0.2 
0g/mL of puromycin. 
Transfection validation: 
Correctly engineered iCRISPR TZM-bl lines were further validated by 
PCR and gel electrophoresis for correct genomic insertion of both Puro-Cas9 and 
Neo-M2rtTA cassettes, by Western Blot to assess inducible Cas9 expression, and 
by immunocytochemical analysis to probe for inducible Cas9 expression and 
localization pattern. 
DNA Isolation 
Genomic DNA from transfected cells was isolated using the QIAmp DNA Mini 
Kit (Qiagen, Hilden, Germany. Cat #: 51304, Lot #: 160010049) according to 
the manufacturer!s protocol. Around � � ��� cells were used for each isolation. 
After elution with 100 0L RNase-free water, nucleic acid concentration was 
measured using a NanoDrop  One/OneC Microvolume UV Spectrophotometer 
(Thermo Fisher Scientific, DE, USA). DNA isolates were stored at -20 ˚C. 
Polymerase Chain Reaction: 
800ng of each DNA isolate was combined with 50 0L of Taq PCR master mix 
(Qiagen, Hilden, Germany. Cat #: 201443, Lot #: 160044355), and 2 0L of 10 
0M forward and reverse primers in PCR tubes. Primers were designed using 
Primer-BLAST,70 and synthetic oligos were manufactured by Integrated DNA 
Technologies, Inc. (IDT, IA, USA). Primer sequences are indicated in Table 3: 
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Table 3. Sequences of PCR Primers Used for Validation of Cassette Genomic Integration  
 
RNase-free water was added to the reaction mix to obtain a final volume of 100 
uL. PCR reactions were carried out in a thermal cycler according to the following 
cycling program (Table 4): 
 
Steps Time Temperature (˚C) 
Initial denaturation 3 mins 94 
3 Step cycling: 
Denaturing 
45s 94 
3 Step cycling: 
Annealing 
45s 
5 degrees below the 
melting temperature of 
primer set 
3 Step cycling:  
Extension 
1 min (Repeat cycling 
35 times) 
72 
Final extension: 10 mins 72 
Hold: Overnight 4 
Table 4. Thermocycling Conditions Used for PCR Reactions. 
Gel Electrophoresis: 
Gel electrophoresis was performed as previously described. 6μL of 6X DNA 
loading dye (ThermoFisher, MA, USA. Cat #: R0611, Lot #: 00606810) was 
&.!
added to each 10 0L of PCR reaction mixture, with 80L of 100bp DNA ladder 
(ThermoFisher, Vilnius, Lithuania. Cat #: SM0321, Lot #: 00714077).  
PCR Purification: 
PCR reaction products were cleaned up using the QIAquick PCR Purification 
Kit (Qiagen, Hilden, Germany. Cat #: 28104, Lot #: 154038972) according to 
the manufacturer!s protocol. 50 0L of PCR reaction product was used for each 
PCR purification reaction. After elution with 100 0L Buffer EB, nucleic acid 
concentration was measured using a NanoDrop  One/OneC Microvolume UV 
Spectrophotometer (ThermoFisher, DE, USA. Machine #:0094684). Purified 
PCR products were stored at -20 ˚C.  
Sanger Sequencing of PCR Products: 
DNA samples were prepared according to Genewiz!s protocol. For each 
sequencing reaction, purified PCR templates were diluted to around 1ng/0L and 
10 0L was aliquoted into 8-strip PCR tubes. Forward primers synthesized for 
PCR reaction were used to identify Cas9 and M2rtTA gene integration and a 
total amount of 25 pmol was used for each sequencing reaction. The total 
sequencing reaction volume that was submitted was 15 0L. 
iCRISPR TZM-bl Cas9 Expression Induction: 
Four iCRISPR TZM-bl lines (Clone 7, 14, 25, and 26) and WT unengineered 
TZM-bl cells were seeded into 6 well plates with around 20% confluency. They 
were cultured for 2 days to reach 50% confluency. They were then treated with 
or without doxycycline (2�g/mL) (Sigma Aldrich, MO, USA. Cat #: D9891-5G, 
Lot #: BCBL3540V) for 2 days. Cells were then lysed with 200 �L 1:1 mixture of 
RIPA buffer (Cell Signaling Technology, Danvers, MA. Cat #: 9806S) and 
protease inhibitor (Santa Cruz Biotechnology, Dallas, TX. Cat #: sc29131) for 20 
mins at room temperature. Lysates were spun down at 10,000 g for 2 mins to 
&%!
remove other insoluble debris and were stored at -20˚C for BCA Protein Assay 
and Western Blot Analysis.  
BCA Protein Assay: 
Protein concentrations of all doxycycline untreated and treated cell lysates were 
assayed using Pierce BCA Protein Assays kit (ThermoFisher, DE, USA. Cat #: 
23225, Lot #: NI177989) according to the manufacturer!s protocol. 25 �L neat 
and 10X diluted cell lysates were used in the assay. Protein concentrations were 
determined using an iMark microplate absorbance reader (BioRad, Hercules, CA. 
Machine #: 15563) with a 570 nm test wavelength and based on the provided 
standard. 
Western Blot: 
Western blot was used to detect the presence of Streptococcus pyogenes Cas9 
proteins in 30 �g of total protein for each iCRISPR TZM-bl cell line. 75 ng of 
TrueCut  Cas9 Protein v2 was used as positive control. All samples were 
brought to final volume of 24 �L using 1X DPBS. 8 0L of Laemmli 4X sample 
buffer (BioRad, CA, USA. Cat #:161-0747 Lot #: 64077737) supplemented with 
10% 2-mercapatolmethanol (Biorad, CA, USA. Cat #: 1610710, Lot #: 
L004109A) was added to each sample. After 5 mins incubation at 95˚C, 30 �L of 
each was loaded into a Criterion TGX 7.5% gel (BioRad, CA, USA. Cat #: 
5678024, Lot #:64086792). The gel was electrophoresed by application of 100V 
for 100 mins. The proteins were then transferred to a PVDF membrane (BioRad, 
Hercules, CA. Cat #: 1620177. Lot #: 30379A12), which was blocked with 3% 
milk (BioRad, CA, USA. Cat #: 1706404. Lot #: 64047053) in 
PBS+0.05%Tween20 (PBST) (Sigma-Aldrich, St. Louis, MO Cat #: 274348 Lot 
#: MKBF5463V) for 1 hour. The membrane was subsequently incubated with 
mouse monoclonal anti-CRISPR-Cas9 [7A9-3A3] primary antibody (Abcam, MA, 
USA. Cat #: ab191468, Lot #:GR3242232-1), at a concentration of 0.1 �g/mL 
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overnight. After washing the membrane with PBST three times, it was incubated 
with a goat anti-mouse IgG-HRP secondary antibody (Santa Cruz Biotechnology, 
TX, USA. Cat #: sc-2005 Lot #: F2718) at a 1:5,000 dilution for 1 h. The 
membrane was then incubated with a 1:1 mixture of SuperSignal West Pico 
Stable Peroxide solution and Luminol Enhancer solution (Thermo Scientific, 
Rockford, IL Cat #: 34080 Lot #: SD246944) for 5 min. The membrane was 
visualized for 150s using Azure c500 Imaging System (Azure Biosystmes, CA, 
USA.Machine #: 0096507).  
Immunocytochemistry: 
iCRISPR and WT TZM-bl cells were cultured in 6-well plates containing sterile 
coverslips. After the same induction schedule as previously described, fixation in 
1mL of freshly prepared 4% paraformaldehyde (Sigma Aldrich, MO, USA. Cat #: 
6148-500G, Lot #: MKCB4217) in PBS was conducted for 20 mins and then 
quenched with 1mL of 10 mM glycine (Biorad, CA, USA. Cat #: 161-0718, Lot 
#: 64027676) in PBS. Cells were then washed 3X with ice-cold PBS. Immediately 
after washing, cells were permeabilized using 0.1% Triton X detergenet (Sigma 
Aldrich, MO, USA. Cat #:, Lot #:) in PBS for 10 mins at room temperature, 
washed with PBS, and then placed in blocking solution (PBS with 2% bovine 
serum albumin (Cell Signaling Techonology, MA, USA. Cat #: 9998S, Lot #: 
20)) for 30 mins. Cells were incubated with mouse monoclonal anti-CRISPR-Cas9 
antibody [7A9-3A3] (Abcam, MA, USA. Cat #: ab191468 Lot #:GR3242232-1) 
in 2% BSA-PBS (1:250 dilution) overnight. After washing with PBS, they were 
then incubated for one hour with FITC conjugated goat anti-mouse IgG F(ab’)2 
secondary antibody (Invitrogen, IL, USA. Cat #: 31543, Lot #: TJ2652971A) 
and washed again. Coverslips were mounted on frosted microscope slides 
(Thermo Scientific, China. Cat #: 2951-001, Lot #: 17348-629238) with 10 µL 
ProLong Gold antifade mountant with DAPI (Invitrogen, OR, USA. Cat #: 
P36931, Lot #: 2030225). Slides were then imaged with Nikon Eclipse 90i (Nikon, 
Japan. Machine ID: 0081647) and analyzed with ImageJ software. 
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TZM-bl Luciferase Assay:  
Luciferase activities were assessed under both induced and uninduced 
conditions. iCRISPR TZM-bl clones and WT TZM-bl cells were induced as 
previously described in 96-well plates. 4 days prior to performing the luciferase 
assay, 15,000 cells of each cell type were seeded into each well. 24 hours after, 
cells on the induction plate would be exposed to doxycycline-containing medium. 
48 hours later, cells on both the uninduced and induced plates were exposed to 
H9/Rf HIV-containing-media from infected cells overnight. The luciferase assay 
was performed according to the manufacturer!s protocol using the Luciferase 
Assay System (Promega, WI, USA. Cat #E1500, Lot #: 0000309373) and was 
read on a Fluoroskan Ascent FL luminometer (Labsystems, USA. Machine #: 
0063969). 
LentiArray  CRISPR Control Lentivirus Particles Transduction 
As preparation for genetic screening using LentiArray  CRISPR libraries, 
CRISPR positive control lentivirus particles (ThermoFisher, CA, USA. Cat#: 
A32069, Lot #:1989459) were used to determine the optimal transduction 
Multiplicity of Infection (MOI) for iCRISPR clones. These positive lentivirus 
particles target the human HPRT gene, which initiates the metabolism of the 
cytotoxic antitumor agent 6-Thioguanine (6-TG). Cells with HPRT gene knocked 
out would be resistant to 6-TG treatment. Transduction was performed as 
described per manufacturer!s protocol, enhanced with 8 �g/mL of Polybrene  
Transfection Reagent (Millipore, Darmstadt, Germany. Cat #: TR-1003-G, Lot 
#:3168045). As the Puro-Cas9 cassette already confers iCRISPR TZM-bl cells 
with puromycin resistance, the puromycin selection phase was omitted as we only 
aim to demonstrate functional gene knock out. 4 days after transduction, 
fluorescent images were taken under the same setting using an Eclipse TE200 
inverted microscope (Nikon Instruments, NY, USA. Machine #: 0072745). After 
7 days, transduced iCRISPR cells were switched to 100 �L medium containing 5 
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µM, 10 µM, and 15 µM 6-thioguanine (6-TG) (Sigma Aldrich, MO, USA. Cat #: 
A4882-100MG, Lot #: SLBW6998) for 5 days. Viability of cells after 6-TG 
treatment was assessed using crystal violet staining. 50 µL 0.5% crystal violet 
solution (0.5g crystal violet powder (Sigma Aldrich, MO, USA. Cat #: C6158-
50G, Lot #: MKBT4497V) dissolved in 80mL of distilled water and 20mL of 
methanol (Fisher Chemical, Venezuela. Cat #: A456-500, Lot #: 187936)) was 
added into each well and the plate was shaken at room temperature for 20 mins 
on a rocker at 20 oscillations per minute. Staining solution was then discarded 
and plates were washed under gentle running water four times. The plates were 
then dried overnight and cells were lysed using 200 µL methanol. Cell viability 
was determined using an iMark microplate absorbance reader (BioRad, Hercules, 
CA. Machine #: 15563) with a 570 nm test wavelength. 
 
2.3 Results: 
iCRISPR Platform for Inducible, Rapid, and Multiplexable Genome Editing in 
HIV Latency Cell Lines 
The overall goal is to engineer inducible Cas9-expressing cell lines, firstly 
the TZM-bl line, that could help us identify cellular factors that are important 
for HIV replication. TZM-bl (previously called JC53BL-13) is an indicator cell 
line derived from a HeLa cell line clone that was engineered to express CD4, 
CCR5, and CXCR4 for HIV infectivity66. The cells also have integrated copies of 
the luciferase gene under transcriptional control of the HIV-1 long terminal 
repeat101, so that the level of HIV infectivity and transcription can be quantified 
by luminescence upon supply of the luciferase substrate. This engineered 
iCRISPR TZM-bl cell line could then be used for identification of candidate host 
factors of interest for HIV infection.   
To prepare an inducible Cas9-containing TZM-bl cell line for a genetic 
screen of HIV-related factors, we introduced two cassettes into TZM-bl HIV 
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reporter cell line via lipid-based transfection and CRISPR-mediated homology-
directed repair (Figure 1A). One cassette contains a doxycycline-inducible Cas9 
gene (Puro-Cas9 donor), and the other carries a constitutive reverse tetracycline 
transactivator (M2rtTA) gene (Neo-M2rtTA donor)97. After a stable iCRISPR 
cell line was established, Cas9 expression would be induced by doxycycline 
treatment and gRNA-containing lentiviral particles from our libraries of interest 
would be delivered for the genetic screens (Figure 1B).  
 
 
Figure 4. Workflow of iCRISPR TZM-bl Cellular Engineering and Genetic Screening  
A) Generation of iCas9 TZM-bl through CRISPR-mediated gene targeting at 
the AAVS1 locus. Both Cas9 and M2rtTA cassettes will be inserted into 
PPP1R12C intron thorugh homology-dependent repair. Red segments indicate the 
homology regions between the donor plasmids and the TZM-bl genome. B) Schematic of 
iCRISPR-based genetic screen. Cas9 protein (blue) expression is induced with 
doxycycline (red dot). Doxycycline binds to M2rtTA (yellow hexagon), which in turns 
binds to TRE (white) to express Cas9. Cas9 protein binds with a gRNA molecule (pink) 
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to induce double stranded break to create gene knock-out for genetic screening purposes. 
TRE: tetracycline response element; CAG: constitutive synthetic promoter; M2rtTA: 
reverse tetracycline transactivator sequence and protein  
 
Before transfecting the TZM-bl cell line, the three plasmids, one AAVS1-
targeting Cas9-gRNA plasmid and the two donor plasmids described above 
obtained from Addgene, were thoroughly characterized. Their identities were 
verified using restriction enzyme digest and Sanger sequencing. Under various 
conditions, the sizes of the undigested, singly digested, and doubly digested 
plasmids were all presented at the correct size (Figure 2A). 2 primers were used 
for the Sanger sequencing of each plasmid and all sequences aligned well (Red 
regions) with the known sequences of the plasmids with minimal mismatch (white 
see-through regions on red arrows) (Figure 2B). 
 
Figure 5. iCRISPR Plasmids Characterization.  
A) Restriction Digest Analysis of all three iCRISPR plasmids. Lane 1: 10kb DNA ladder; 
Lane 2: undigested Cas9 plasmid; Lane 3: AgeI digested Cas9 plasmid; Lane 4: 
AgeI+SpeI digested Cas9 plasmid; Lane 5: undigested M2rtTA plasmid; Lane 6: EcoRV 
digested M2rtTA plasmid; Lane 7: EcoRV+NheI digested Cas9 plasmid; Lane 8: 
undigested AAVS1-CRISPR plasmid; Lane 9: EcoRI digested AAVS1-CRISPR plasmid; 
Lane 10: EcoRI+XbaI digested AAVS1-CRISPR plasmid. B) Sanger sequencing of three 
iCRISPR plasmids. Red arrows indicate homology between Sanger sequences with 
plasmid templates.  
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After comprehensive characterization of the plasmids, all three plasmids 
were introduced into TZM-bl cells using lipofectamine-based co-transfection. 
Transfected cells underwent one month of antibiotic selection to ensure a 
homogenous edited cell population. To comprehensively characterize the cell line, 
nuclear DNA was extracted from confluent clones, and successful genomic 
integration of both Cas9 and M2rtTA cassettes was confirmed in five (Clones 7, 
14, 25, 26, 27) out of eleven clones using PCR and Gel Electrophoresis (Figure 
3A). Western blot analysis also confirmed the induction of Cas9 expression upon 
doxycycline treatment in all four out of the five iCRISPR clones remained 
(Clones 7, 14, 25, 26) (Figure 3B). Clone 27 was not viable after successive 
passaging and selection using two antibiotics. Immunocytochemical analysis also 
revealed the presence of Cas9 protein in all clonal iCas9 lines, primarily localized 
in the cytosol without gRNA presence (Figure 3C). After all engineered iCRISPR 
TZM-bl clones were characterized at the DNA and protein level, the functionality 
of the iCRISPR clones was assessed to ascertain the intact reporter functionality 
of this cell line. Luciferase reporter activity of iCRISPR clonal lines was 
compared to WT TZM-bl cells under both uninduced and induced condition. 
Regardless of the production of Cas9 protein, all clonal lines besides clone 26 
exhibited regular luciferase activity under the same infection condition (Figure 
3D). Clone 26 was then excluded from future experiments since the elevated 
luciferase level would confound our findings in the future genetic screens. 
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Figure 6. Baseline Cellular Characterization of iCRISPR TZM-bl Clonal Lines  
A) PCR analysis of iCRISPR TZM-bl clones. 5 lanes in which the clones carrying desired 
cassette insertions in the AAVS1 locus are outlined in yellow. CA: Cas9/AAVS1 primers; 
MA: M2rtTA/AAVS1 primers. NC: negative control (WT TZM-bl DNA), PC: positive 
control (plasmids with known primer binding sites), NTC: No template control (𝐻(𝑂) B) 
Immunocytochemical analysis of Cas9 protein expression in all 4 iCRISPR TZM-bl 
clonal lines with or without doxycycline treatment. WT TZM-bl cells were used as the 
negative control. White arrows in Clone 14 indicates faint green fluorescent signals 
compare to the negative control.  C) Western blot analysis of Cas9 protein expression in 
4 iCRISPR TZM-bl clonal lines with or without doxycycline treatment. WT TZM-bl 
cells were used as the negative control and commercially isolated Cas9 protein was used 
as positive control. D) Luciferase reporter activity of in 4 iCRISPR TZM-bl clonal lines 
with or without doxycycline treatment. WT TZM-bl cells were used as the negative 
control; *** p<0.0001 (2 way ANOVA using Sidak’s multiple comparisons test and 
followed by Holme-Sidak correction for multiple tests). 
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The functionality of induced Cas9 protein was assessed in clone seven via 
6-thioguanine resistance assay after the cells were transduced with human HPRT 
targeting lentiviruses. Optimal MOI was determined using various dilutions of 
lentiviral particles, and transduction efficiency was determined under a 
fluorescent microscope. MOIs of 1 and 0.1 were sufficient for transduction (Figure 
4A left+right panels). iCRISPR clone7 demonstrated fully functional Cas9 
proteins, as cells effectively have the HPRT gene knocked out were viable under 
6-TG treatment compared with mock-transduced iCRISPR clonal cells (Figure 
4B, C).  
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Figure 7. Transduction Functional Characterization of iCRISPR TZM-bl Clonal Lines.  
A) Light and Fluorescent microscopy images of transduced iCRISPR TZM-bl clonal 
lines. Visible GFP signals were present in iCRISPR TZM-bl cells transduced with MOI 
of 1 and 1023. WT TZM-bl cells were transduced with the highest MOI and mock 
transduced iCRISPR cells were included as negative controls. B) Pictures of crystal 
violet staining of transduced iCRISPR cells after 6-TG treatment. C) Quantification of 
crystal violet staining assay using OD at 570nm. MOI of 1 and 1023 were sufficient to 




Overall, iCRISPR TZM-bl cell lines have now been engineered with stable 
genomic integration of inducible Cas9. As an HIV indicator cell line, iCRISPR 
TZM-bl cell lines will now be used to screen host factors, including EV 
recognition molecules, that may affect susceptibility to HIV infection and 
capacity for HIV transcription.  
By directly targeting the AAVS1 locus that is considered a safe harbor, 
the AAVS1 targeting approach that we took minimized the unpredictable effect 
of random transgene insertion through the traditional retroviral and lentiviral 
factors102. This directed insertion can be illustrated by the negative correlation 
between the amount of Puro-Cas9 amplicon and that of Neo-M2rtTA amplicon in 
the gel (Figure 3A), as there were limited AAVS1 loci in the genome available for 
insertion. One caveat that should be considered when targeting transgenes into 
AAVS1 locus is the fact that there exists a high degree of aneuploidy in 
immortalized cell lines. As demonstrated by Landry and colleagues, the HeLa 
cells, the parental line of TZM-bl, has a high degree of genomic segmentation and 
rearrangements103. As the transcriptomic profile is altered, the acceptability of 
using this cell line for genetic screening would be compromised.  
As illustrated in the immunocytochemistry images (Figure 3B), the 
resultant clonal cells are mixed populations of engineered and non-engineered 
cells even after a long period of antibiotic selection. The heterogeneous nature of 
the clones with unpredictable genotype could benefit from a more efficient and 
uniform method of generating an iCRISPR system such as by combining 
CRISPR/Cas9-mediated genome editing with the Flp/FRT and Cre/LoxP 
system104. Not only intercellularly, but there also exist interclonal differences on 
translational and functional profiles. There is a stark difference in the percentage 
of Cas9 positively stained cells assessed by immunocytochemistry (Clone 14) and 
a difference in basal luciferase activities with or without doxycycline induction 
compared to the WT TZM-bl cells (Clone 26).  
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One thing to note is the importance of optimization in the initial phase of 
the experiments. Starting with plasmid transfection, the concentration of 
lipofectamine and nucleic acids that yielded a higher transfection efficiency was 
one μL Lipofectamine: one μg plasmid DNA, as the transfected cells reached 
confluence faster under antibiotic selection than cells under any other transfection 
conditions. In addition, each clone responded to various antibiotics differently, 
which required rigorous optimization of adequate concentrations of the 
antibiotics. To accomplish this, we implemented dose-response experiments to 
assess the antibiotic kill curve. These optimizations are critical to the success of 
cellular engineering. 
A potential pitfall of this focused screen is that we may miss important 
factors or fail because gene combinations are needed to produce the effects, so we 
might not see any change in luciferase intensity in our genetic screen. Another 
potential pitfall is that there exist gene redundancies to complement the impact 
of gene knock out and we would likely to see no consequences either. These 
potential pitfalls could be circumvented by combining lentiviral particles that 
target multiple genes in a known pathway together and see the effect of certain 
established ontological pathways on the maintenance of HIV latency. 
The high frequency of off-target activity could induce genetic changes at 
sites other than the on-site targets105–108. While full-scale genomic sequencing to 
rule out all off-target effects might be hard to achieve, we suggest that the 
repeated confirmation step is sufficient to dismiss a likely role for such activity. 
We could also verify that the results are indeed due to intended knock out by 
rescuing the phenotype with a plasmid encoding the WT gene that was knocked 
out.  
Multiple HIV latent cell lines should be used in the next phase of the 
screening to ensure a validated result that has biological significance. In Sunshine 
and colleague’s paper, they have discovered that four of the commonly used HIV 
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latency cellular models are significantly different from patient samples, both in 
terms of HIV integration sites and gene expression profiles109. 
This thesis provided evidence for the feasibility of the cellular engineering 
methodology that we employed and illustrated the versatility of this method in a 
diverse range of genetic screening projects. CRISPR-mediated knock-in using 
plasmid transfection worked well for this cell line and could potentially be used 
for any cell line of interest. For the engineered TZM-bl cells, we would likely 
deliver any gRNA of interest using a variety of methods to investigate the 
functionality of specific genes on the HIV life cycle. 
Overall, one cell line has been engineered and fully characterized. The next 
step is to conduct an initial multiplex genetic screen with the commercial 
Membrane Trafficking Library to identify what are some potential cellular genes 
that are important in the HIV life cycle. The top candidates with the most 
substantial readout alterations would be validated again by individual knock-out 
experiments.  After the initial screening in iCRISPR TZM-bl cell line, we would 
like to establish this iCRISPR platform in HIV latent monocytic U1 and 
lymphocytic ACH2 cell lines, to identify factors that could contribute to the 
sensing of EVs and the maintenance of HIV latency. The same lentivirus libraries 
would be used for genetic screens in these latency cell lines. Knock out of genes 
that produced the most considerable HIV latency reversal would be verified again 
using Bcl-2-transduced primary T-cell latency model that better recapitulate the 
quiescent state of restingCD4+ T cells in vivo110. Verified genes will be used for 
gene ontological analysis to elucidate the putative cellular mechanisms that could 
contribute to HIV latency maintenance.  
This project will deliver novel insights into EV sensing by cells and how 
these interactions affect lipid metabolism and HIV latency. Druggable targets will 
be identified for adjunct HIV latency reversal approaches  
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